Drug Approval | December 28, 2021
Sun Pharma receives DCGI approval for Molxvir in India
The product is expected to be available in a week’s time
The product is expected to be available in a week’s time
The company will market it under the brand name Molflu
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Expertise in exosomes isolation and characterization will drive innovation in this field
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Subscribe To Our Newsletter & Stay Updated
